EU approves Abilify Maintena, first for Lundbeck/Otsuka alliance
This article was originally published in Scrip
Executive Summary
The European Commission has approved Otsuka and Lundbeck's once-monthly schizophrenia drug Abilify Maintena (aripiprazole), which the two companies will co-commercialize across the European Union. The approval is important for Otsuka in particular, as it may stave off some of the sales damage likely to be caused by the imminent launch of generic aripiprazole, which will compete with the oral version of the drug marketed as Abilify.